Feed & Additive Magazine Issue 2 March 2021

NEWS FEED & ADDITIVE MAGAZINE March 2021 31 Myande supplies 3D technology for biological feed additives project The intelligent equipment line, with an annual output of 50,000 tons of biological feed additives, is supplied by Myande. F angchenggang Ausca Oil Company has recently es- tablished a joint laboratory with Jiangnan University’s National Engineering Laboratory for Ce- real Fermentation Technology. This new laboratory is aimed at developing biological feed strain breeding and research in produc- tion technology and its industri- al application. Ausca Biological Feed Additives project is one ex- ample of the industrial applica- tion of the research results of the joint laboratory. The intelligent equipment line, with an annual output of 50,000 tons of biological feed additives, is supplied by Myande. Myande’s scope of work includes complete process of raw material receiving, mixing, anaerobic fermentation, drying and cooling, crushing and packaging. Eight intelligent rect- angular fermentation beds and a sealing system are equipped to achieve the purpose of anaerobic fermentation, as well as the auto- matic material placing machine and discharging machine to real- ize automatic production. In ad- dition, the fluidized bed drying tower which is newly designed by Myande is adopted in the drying section, which can meet the pro- cess requirements of large-output drying. During the design process of Ausca fermentation project, Myande design team worked closely to complete the entire de- sign task with high quality within a tight schedule. During the con- struction of the project, when the overall completion of the proj- ect reaches 30%, 60% and 90% of the design nodes, the process, civil engineering and 3D design team will jointly review the mod- el of the entire factory. In this way, problems and difficulties in the design can be discovered in time, then reasonable improve- ment measures can be taken, and continuous optimization of the factory process can be realized during the design process. Elanco’s Increxxa receives FDA approval Increxxa™ (tulathromycin injection) was approved by the FDA for U.S. cattle and swine producers and veterinarians, Elanco Animal Health announced. E lanco Animal Health Inc. announced the U.S. Food and Drug Administration (FDA) approval of Increxxa™ (tulathromycin injection) for the treatment of bovine respiratory disease (BRD) and swine respiratory disease (SRD). “We recognize what a challenge respiratory dis- ease can be for the livestock industry and are excit- ed to offer Increxxa to veterinarians and producers, giving them yet another solution to help combat this problematic disease in cattle and swine,” said Jose Simas, executive vice president, U.S. farm an- imal business at Elanco. “Like all Elanco products, veterinarians and producers can be confident that Increxxa is held to the company’s uncompromising standard of potency, uniformity and quality.”